Anti Cancer Capsules

Product Details:

Nintib 100 Soft Gelatin Capsule is used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer. It works by targeting certain pathways involved in the growth and progression of these diseases and helps to stop or slow the spread of cancer cells.

Nintib 100 Soft Gelatin Capsule should be taken with food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is a very common side effect of this medicine. You are advised to drink plenty of fluids and inform your doctor if it does not go away. Other common side effects include nausea, abdominal pain, vomiting, abnormal liver function tests, loss of appetite, headache, weight loss, and high blood pressure. Your doctor might ask you for some blood tests to monitor liver functioning.

Before taking it, tell your doctor if have a bleeding problem, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Product Details:

Pyrotinib maleate, also known as pyrotinib, is an irreversible dual receptor tyrosine kinase inhibitor that primarily targets the epidermal growth factor Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) drug targeting epidermal growth factor receptor (EGFR), HER1, HER2, and HER4 (Zhu et al., 2016; Li et al., 2017), and it has shown promising antitumor activities in patients with HER2-positive metastatic breast cancer according to the ...receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).

Product Details:

Zanubrutinib (Brukinsa, 80 mg oral capsules) is a second-generation BTK inhibitor indicated for the treatment of adult patients with WM. It received a Notice of Compliance from Health Canada on March 1, 2021.